


Existence of Carcinogenic Threshold : Evidence from Mechanism-Based Carcinogenicity Studies

Shoji Fukushima, M.D., Ph.D.

**Japan Bioassay Research Center,
Japan Industrial Safety and Health Association**



Genotoxic



Genotoxic

- Environmental carcinogens**
- Genotoxic or non-genotoxic
 - Natural or synthetic
 - Cooking process, contamination, or synthesis in the body
 - Avoidable or unavoidable
 - Human intake, 1.5 g/day (B. Ames)




Genotoxic

Non-genotoxic




Present concept of chemical carcinogenicity

Low-dose carcinogenicity curve of **genotoxic (mutagenic) carcinogens**:
Extrapolation from high to low doses



- It is generally considered that genotoxic carcinogens have no threshold in carcinogenic potential. This hypothesis has led to acceptance of linear curve that approach zero at low doses for risk assessment. There are, however, limited data available for these hypothesis.
- It has been argued that non-threshold theory is challenged based on the view that organism possess biological responses that can be ameliorate genotoxic activities.
- Therefore, it is important to resolve this question from the view point of cancer risk assessment and management.

Merit of a medium-term bioassay for carcinogens




Liver medium-term bioassay


Liver



Number-Area / unit of glutathione S-transferase placental form (GST-P) positive foci




Carcinogenicity test




Incidence of tumors

Chemical carcinogenesis mechanism




MelQx



2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline


- One of heterocyclic amines
- Exists in well-cooked fish and meat
- Mutagenicity: positive
- Hepatocarcinogen
- Human exposure level : 0.2-2.6 $\mu\text{g}/\text{day}$






MelQx: 2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline

(Wakabayashi et al, 1995)

Rat hepatocarcinogenicity of MeIQx at low doses



Animals : 1,180 male F344 rats, 21-day-old
 Number (/cm²)



MeIQx




Big Blue Rat

lacI gene : 30~40 copies on chromosome 4 in the F344 rat




Liver


DNA isolation




in vitro packaging



Phage





**Infection E.coli
Incubation containing X-gal**



**Blue plaque=Mutation (+)
White plaque=Mutation (-)**


***In vivo* mutagenicity test in Big Blue rats
(Plaque Color Screening Assay)**

Incidence of *lacI* gene mutations and development of GST-P positive foci in the liver of Big Blue rats treated with MelQx for 16 weeks




lacI gene: 30~40 copies on chromosome 4 in the F344 rat

Frequencies of H-*ras* mutation and GST-P positive foci in the liver of rats treated with MeIQx



Detection of H-*ras* mutation:
Thermosequenase cycle end labeling (TCEL) method

Chemical carcinogenesis mechanism




Initiation activity of MeIQx at low doses in the rat liver







Animals: 850 male F344 rats, 21-day-old


MeIQx; 0, 0.001, 0.01, 0.1, 1, 10, 100 ppm in diet



MelQx DNA adduct level and number of GST-P positive foci in the damaged liver of rats



Risk of liver cancer: Response curves for the carcinogenicity markers dependent on the dose of MeIQx



**Conclusion: Existence of a carcinogenic threshold,
at least a practical threshold**


Assessment of genotoxic carcinogens at low doses

Effects on various organs

Liver, Colon, Kidney

Effects on various biomarker

1. Carcinogen-DNA adduct
2. *In vivo* mutagenicity
Mutation frequency of lacI or gpt gene
3. Oxidative DNA damage: 8-OHdG
4. Preneoplastic lesion
Liver: GST-P positive foci
Kidney: atypical tubular hyperplasia
Colon: Aberrant crypt foci (ACF)
5. Tumor



Weights of evidence

Effects of IQ on development of GST-P positive foci and DNA adduct formation in livers of rats



Animal: 1,560 male F344 rats, 21-day-old


IQ : 0, 0.001, 0.01, 0.1, 1, 10, 100 ppm in diet

GST-P positive foci







IQ (ppm)	No. of rat	GST-P positive foci (No./cm ²)
0	240	0.15 ± 0.31
0.001	240	0.16 ± 0.31
0.01	240	0.26 ± 1.30
0.1	240	0.15 ± 0.35
1	240	0.14 ± 0.33
10	240	0.74 ± 0.88 *
100	120	88.03 ± 50.41 *

* p<0.01 v.s. 0 ppm

IQ-DNA adduct




mRNA expression in liver of IQ-treated rats at week 16



*p<0.05 v.s. 0 ppm

PhIP





One of food-derived heterocyclic amines

Mutagenicity: positive


Carcinogenicity: colon

Daily intake: 0.005-0.3 µg/day

Rat colon carcinogenicity of PhIP at low doses: Aberrant crypt foci (ACF) and PhIP-DNA adducts



ACF in colon




PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine

PhIP carcinogenicity in azoxymethane-initiated rat colon carcinogenesis




Animals: 192 male, 6-week-old, F344 rats

Tumor: Adenoma + Carcinoma



PhIP dose (ppm)



PhIPdose (ppm)

N-Nitroso Compounds

- **Air, water, and food, notably in nitrite-treated meat and fish products**
- ***in vivo* formation from nitrites or nitrates and secondary amines**
- **Diethylnitrosamine**
- **Dimethylnitrosamine**
- **Mutagen**
- **Hepatocarcinogen**
- **Daily intake : $\mu\text{g}/\text{day}$ range level**

Rat hepatocarcinogenicity of *N*-nitroso compounds: Induction of GST-P positive foci

0 16 weeks



Diethylnitrosamine (DEN)

male F344, 21-day-old, 1,957 rats



0 16 weeks

Dimethylnitrosamine (DMN)


male F344, 21-day-old, 1,520 rats



LacI mutation frequency and development of GST-P positive foci in the liver of Big Blue rats treated with DEN for 16 weeks



Potassium bromate



Potassium bromate
(KBrO₃)

Food additive

Contaminant in tap water

Genotoxicity

Ames test: +

Chromosome aberration test: +


Micronucleus assay: +

Renal carcinogenicity in rats


≥250 ppm: + (Kurokawa Y, 1983)

Mutation frequencies and oxidative DNA damage in kidney of Big Blue rats treated with potassium bromate

0 16 weeks
5 rats/group **KBrO₃, 0, 0.02, 0.2, 2, 8, 30, 125, 500 ppm**
KBrO₃: potassium bromate



Promotion effects of KBrO_3 in kidney carcinogenesis induced by EHEN in Wistar rats




Animal: 240, 6-week-old, male Wistar rats




* 500 → 250 ppm from week 12

Kidney: 8 slices/kidney (16 slices/rat)

Renal tumor




Atypical tubular hyperplasia



Conclusions


Response curves for the effects of genotoxic carcinogens dependent on the dose

Carcinogenicity at **high dose**



← Dose used in the previous experiment →

Carcinogenicity at **low dose**



← Dose used in the present experiment →

Existence of threshold (practical or perfect)

Thresholds in carcinogenicity

Recently, the concepts of “practical” and “perfect” thresholds for genotoxic carcinogens have been proposed. In these cases, activities of carcinogens are usually associated with a no-observed effect level (NOEL).

Genotoxic carcinogens and thresholds

1. **Primary mutagenic carcinogen**
 - **Practical threshold**
 - : Heterocyclic amines, *N*-nitroso compounds
2. **Secondary mutagenic carcinogen**
 - **Perfect threshold**
 - : Potassium bromate
3. **Primary or secondary mutagenic carcinogen, but carcinogenicity based on cytotoxic mechanism**
 - **Perfect threshold**
 - : 1,4-Dioxane
4. **Genotoxic, but non-mutagenic carcinogen**
 - **Perfect threshold**
 - : Dimethylarsinic acid

Risk assessment for genotoxic carcinogens in near future

Since the threshold exists for genotoxic carcinogens, we should accept it for human risk assessment and management of environmental carcinogens, in particular for substances contained in food at low doses.

Collaborators

Hirose, Masao (Div. of Pathology, National Institute of Health Sciences)

Konishi, Yoichi (Dept. of Oncological Pathology, Cancer center, Nara Medical University)

Nakae, Dai (Dept. of Pathology, Sasaki Institute, Sasaki Foundation)

Otani, Shuzo (Dept. of Biochemistry, Osaka City University Med. Sch.)

Shirai, Tomoyuki (Dept. of Pathology, Nagoya City University Med. Sch.)

Takahashi, Michihito (Div. of Pathology, National Institute of Health Sciences)

Tatematsu, Masae (Div. of Oncological Pathology, Aichi Cancer Center Research Institute)

**Tsuda, Hiroyuki (Experimental Pathology and Chemotherapy Div.,
National Cancer Center Research Institute)**

**Wakabayashi, Keiji (Cancer Prevention Research,
National Cancer Center Research Institute)**

